Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01603394 · ClinicalTrials.gov registry record · Phase 4
Pilot Study Of Pregabalin And Prediction Of Treatment Response In Patients With Postherpetic Neuralgia
A Phase 4 study, sponsored by Pfizer.
- Terminated
- Registry status
- Phase 4
- Development phase
- 9
- Enrollment target
NCT01603394: Clinical Trial Phase 4 study, sponsored by Pfizer.
NCT01603394 is a Phase 4 study that was terminated before completion, run by Pfizer. The registered enrollment target is 9 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (98% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01603394, a Phase 4 study, was terminated before completion, sponsored by Pfizer.
- TERMINATED
- Registry status
- Phase 4
- Development phase
- 9 participants
- Enrollment target
Study Summary
The primary objective is to explore whether sensory symptom cluster analysis is useful for predicting treatment response in Postherpetic Neuralgia.
Primary Outcome
The numeric rating scale for pain (NRS-Pain) consists of an 11-point NRS ranging from 0 (no pain) to 10 (worst possible pain). A rating of 1-3 is considered mild pain; 4-6, moderate pain; and 7-10, severe pain.
Interventions
- DRUG pregabalin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 9 participants |
| Start Date | 2012-10 |
| Est. Completion | 2013-06 |
| Phase | Phase 4 |
Why NCT01603394 stopped before completion
NCT01603394 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 9 participants, a relatively small participant target, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (98% lower).
The record links to 0 conditions, and to 1 intervention - of which pregabalin is the first listed.
NCT01603394 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01603394 about?
NCT01603394 is a clinical study titled "Pilot Study Of Pregabalin And Prediction Of Treatment Response In Patients With Postherpetic Neuralgia". The primary objective is to explore whether sensory symptom cluster analysis is useful for predicting treatment response in Postherpetic Neuralgia.
What is the current status of trial NCT01603394?
This trial is currently terminated. It is a Phase 4 study. The enrollment target is 9 participants. The study started on 2012-10. Estimated completion is 2013-06.
What interventions are being tested in trial NCT01603394?
The interventions under investigation include: pregabalin (DRUG).
Who is sponsoring clinical trial NCT01603394?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01603394's enrollment target sits among peer trials
9 1968th of 2000 higher than 29 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia